ANAnita Vibsig Neutzsky-Wulff

Anita Vibsig Neutzsky-Wulff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anita Vibsig Neutzsky-Wulff has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Interleukin‐15‐activated natural killer cells kill autologous osteoclasts via LFA‐1, DNAM‐1 and TRAIL, and inhibit osteoclast‐mediated bone erosion in vitro

    by Shan Feng, Suzi H. Madsen, Natasja N. Viller, Anita V. Neutzsky‐Wulff, Carsten Geisler, Lars Karlsson, Kalle Söderström

    Osteoclasts reside on bone and are the main bone resorbing cells playing an important role in bone homeostasis, while natural killer (NK) cells are bone‐marrow‐derived cells known to play a crucial role in immune defence against viral infections. Although mature NK cells traffic through bone marrow as well as to inflammatory sites associated with enhanced bone erosion, including the joints of patients with rheumatoid arthritis, little is known about the impact NK cells may have on mature osteoclasts and bone erosion. We studied the interaction between human NK cells and autologous monocyte‐derived osteoclasts from healthy donors in vitro. We show that osteoclasts express numerous ligands for receptors present on activated NK cells. Co‐culture experiments revealed that interleukin‐15‐activated, but not resting, NK cells trigger osteoclast apoptosis in a dose‐dependent manner, resulting in drastically decreased bone erosion. Suppression of bone erosion requires contact between NK cells and osteoclasts, but soluble factors also play a minor role. Antibodies masking leucocyte function‐associated antigen‐1, DNAX accessory molecule‐1 or tumour necrosis factor‐related apoptosis‐inducing ligand enhance osteoclast survival when co‐cultured with activated NK cells and restore the capacity of osteoclasts to erode bone. These results suggest that interleukin‐15‐activated NK cells may directly affect bone erosion under physiological and pathological conditions.


  • Open Access

    Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: How markers of β-cell loss may assist

    by Anita V Neutzsky-Wulff, Kim V Andreassen, Sara T Hjuler, Michael Feigh, Anne-Christine Bay-Jensen, Qinlong Zheng, Kim Henriksen, Morten A Karsdal

    Disease heterogeneity is as major issue in Type II Diabetes Mellitus (T2DM), and this patient inter-variability might not be sufficiently reflected by measurements of glycated haemoglobin (HbA1c). Β-cell dysfunction and β-cell death are initiating factors in development of T2DM. In fact, β-cells are known vanish prior to the development of T2DM, and autopsy of overt T2DM patients have shown a 60% reduction in β-cell mass. As the decline in β-cell function and mass have been proven to be pathological traits in T2DM, methods for evaluating β-cell loss is becoming of more interest. However, evaluation of β-cell death or loss is currently invasive and unattainable for the vast majority of diabetes patients. Serological markers, reflecting β-cell loss would be advantageous to detect and monitor progression of T2DM. Biomarkers with such capacities could be neo-epitopes of proteins with high β-cell specificity containing post translational modifications. Such tools may segregate T2DM patients into more appropriate treatment groups, based on their β-cell status, which is currently not possible. Presently individuals presenting with adequately elevated levels of both insulin and glucose are classified as T2DM patients, while an important subdivision of those is pending, namely those patients with sufficient β-cell capacity and those without. This may warrant two very different treatment options and patient care paths. Serological biomarkers reflecting β-cell health status may also assist development of new drugs for T2DM and aid physicians in better characterization of individual patients and tailor individual treatments and patient care protocols.


  • A specific subtype of osteoclasts secretes factors inducing nodule formation by osteoblasts

    by Kim Henriksen, Kim V. Andreassen, Christian S. Thudium, Karoline N.S. Gudmann, Ilana Moscatelli, Catherine E. Crüger-Hansen, Ansgar S. Schulz, Morten H. Dziegiel, Johan Richter, Morten A. Karsdal, et al.


  • Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta‐cell area and function in Zucker diabetic fatty rats

    by M Feigh, Kv Andreassen, Av Neutzsky‐Wulff, St Petersen, C Hansen, Ac Bay‐Jensen, Je Henriksen, H Beck‐Nielsen, C Christiansen, K Henriksen, et al.

    BACKGROUND AND PURPOSE: Oral salmon calcitonin (sCT), a dual‐action amylin and calcitonin receptor agonist, improved glucose homeostasis in diet‐induced obese rats. Here, we have evaluated the anti‐diabetic efficacy of oral sCT using parameters of glycaemic control and beta‐cell morphology in male Zucker diabetic fatty (ZDF) rats, a model of type 2 diabetes.EXPERIMENTAL APPROACH: Male ZDF rats were treated with oral sCT (0.5, 1.0 or 2 mg·kg−1) or oral vehicle twice daily from age 8 to 18 weeks. Zucker lean rats served as control group. Fasting and non‐fasted blood glucose, glycosylated haemoglobin (HbA1c) and levels of pancreas and incretin hormones were determined. Oral glucose tolerance test and i.p. glucose tolerance test were compared, and beta‐cell area and function were evaluated.KEY RESULTS: Oral sCT treatment dose‐dependently attenuated fasting and non‐fasted hyperglycaemia during the intervention period. At the end of the study period, oral sCT treatment by dose decreased diabetic hyperglycaemia by ∼9 mM and reduced HbA1c levels by 1.7%. Furthermore, a pronounced reduction in glucose excursions was dose‐dependently observed for oral sCT treatment during oral glucose tolerance test. In addition, oral sCT treatment sustained hyperinsulinaemia and attenuated hyperglucagonaemia and hypersecretion of total glucagon‐like peptide‐1 predominantly in the basal state. Lastly, oral sCT treatment dose‐dependently improved pancreatic beta‐cell function and beta‐cell area at study end.CONCLUSIONS AND IMPLICATIONS: Oral sCT attenuated diabetic hyperglycaemia in male ZDF rats by improving postprandial glycaemic control, exerting an insulinotropic and glucagonostatic action in the basal state and by preserving pancreatic beta‐cell function and beta‐cell area.


  • Open Access

    Dissociation of Bone Resorption and Bone Formation in Adult Mice with a Non-Functional V-ATPase in Osteoclasts Leads to Increased Bone Strength

    by Kim Henriksen, Carmen Flores, Jesper S. Thomsen, Anne-Marie Brüel, Christian S. Thudium, Anita V. Neutzsky-Wulff, Geerling E. J. Langenbach, Natalie Sims, Maria Askmyr, Thomas J. Martin, et al.

    Osteopetrosis caused by defective acid secretion by the osteoclast, is characterized by defective bone resorption, increased osteoclast numbers, while bone formation is normal or increased. In contrast the bones are of poor quality, despite this uncoupling of formation from resorption. To shed light on the effect of uncoupling in adult mice with respect to bone strength, we transplanted irradiated three-month old normal mice with hematopoietic stem cells from control or oc/oc mice, which have defective acid secretion, and followed them for 12 to 28 weeks. Engraftment levels were assessed by flow cytometry of peripheral blood. Serum samples were collected every six weeks for measurement of bone turnover markers. At termination bones were collected for µCT and mechanical testing. An engraftment level of 98% was obtained. From week 6 until termination bone resorption was significantly reduced, while the osteoclast number was increased when comparing oc/oc to controls. Bone formation was elevated at week 6, normalized at week 12, and reduced onwards. µCT and mechanical analyses of femurs and vertebrae showed increased bone volume and bone strength of cortical and trabecular bone. In conclusion, these data show that attenuation of acid secretion in adult mice leads to uncoupling and improves bone strength.


  • Dissociation of Bone Resorption and Bone Formation in Adult Mice with a Non-Functional V-ATPase in Osteoclasts Leads to Increased Bone Strength

    by Kim Henriksen, Carmen Flores, Jesper Skovhus Thomsen, Anne-Marie Bruel, Christian Schneider Thudium, Anita Vibsig Neutzsky-Wulff, Geerling Ej Langenbach, Natalie A Sims, Maria Askmyr, Thomas J Martin, et al.

    Osteopetrosis caused by defective acid secretion by the osteoclast, is characterized by defective bone resorption, increased osteoclast numbers, while bone formation is normal or increased. In contrast the bones are of poor quality, despite this uncoupling of formation from resorption. To shed light on the effect of uncoupling in adult mice with respect to bone quality, we transplanted irradiated three-month old normal mice with fetal liver cells from control or oc/oc mice, which have defective acid secretion, and followed them for 12 to 28 weeks. Engraftment levels were assessed by flow cytometry of peripheral blood. Serum samples were collected every six weeks for measurement of bone turnover markers. At termination bones were collected for μCT and mechanical testing. An engraftment level of 98% was obtained. From week 6 until termination bone resorption was significantly reduced, while the osteoclast number was increased when comparing oc/oc to controls. Bone formation was elevated at week 6, normalized at week 12, and reduced onwards. μCT and mechanical analyses of femurs and vertebrae showed increased bone volume and bone strength of cortical and trabecular bone. In conclusion, these data show that attenuation of acid secretion in adult mice leads to uncoupling and improves bone strength. Sources of Research Support: The Danish Research Foundation. Disclosures: MAK: Employee, Nordic Bioscience A/S. Nothing to Disclose: KH, CF, JST, A-MB, CST, AVN-W, GEJL, NAS, MA, TJM, VE, JR

  • Severe developmental bone phenotype in ClC-7 deficient mice

    by A.V. Neutzsky-Wulff, N.A. Sims, C. Supanchart, U. Kornak, D. Felsenberg, I.J. Poulton, T.J. Martin, M.A. Karsdal, K. Henriksen


  • Open Access

    Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality

    by Anita V Neutzsky-Wulff, Mette G Sørensen, Dino Kocijancic, Diana J Leeming, Morten H Dziegiel, Morten A Karsdal, Kim Henriksen

    Background: Normal osteoclasts resorb bone by secretion of acid and proteases. Recent studies of patients with loss of function mutations affecting either of these processes have indicated a divergence in osteoclastic phenotypes. These difference in osteoclast phenotypes may directly or indirectly have secondary effects on bone remodeling, a process which is of importance for the pathogenesis of both osteoporosis and osteoarthritis. We treated human osteoclasts with different inhibitors and characterized their resulting function. Methods: Human CD14 + monocytes were differentiated into mature osteoclasts using RANKL and M-CSF. The osteoclasts were cultured on bone in the presence or absence of various inhibitors: Inhibitors of acidification (bafilomycin A1, diphyllin, ethoxyzolamide), inhibitors of proteolysis (E64, GM6001), or a bisphosphonate (ibandronate). Osteoclast numbers and bone resorption were monitored by measurements of TRACP activity, the release of calcium, CTX-I and ICTP, as well as by counting resorption pits. Results: All inhibitors of acidification were equally potent with respect to inhibition of both organic and inorganic resorption. In contrast, inhibition of proteolysis by E64 potently reduced organic resorption, but only modestly suppressed inorganic resorption. GM6001 alone did not greatly affect bone resorption. However, when GM6001 and E64 were combined, a complete abrogation of organic bone resorption was observed, without a great effect on inorganic resorption. Ibandronate abrogated both organic and inorganic resorption at all concentrations tested [0.3-100 μM], however, this treatment dramatically reduced TRACP activity. Conclusions: We present evidence highlighting important differences with respect to osteoclast function, when comparing the different types of osteoclast inhibitors. Each class of osteoclast inhibitors will lead to different alterations in osteoclast quality, which secondarily may lead to different bone qualities.


  • Local communication on and within bone controls bone remodeling

    by Kim Henriksen, Anita V. Neutzsky-Wulff, Lynda F. Bonewald, Morten A. Karsdal


  • Characterization of acid flux in osteoclasts from patients harboring a G215R mutation in ClC-7

    by Kim Henriksen, Jeppe Gram, Anita Vibsig Neutzsky-Wulff, Vicki Kaiser Jensen, Morten H. Dziegiel, Jens Bollerslev, Morten A. Karsdal